Shares of Biomarin Pharmaceutical BMRN decreased in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 79.55% over the past year to $0.09, which beat the estimate of ($0.10).
Revenue of $486,030,000 decreased by 3.19% year over year, which beat the estimate of $446,450,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
The upcoming fiscal year's revenue expected to be between $1,750,000,000 and $1,850,000,000.
Details Of The Call
Date: Apr 29, 2021
Time: 04:30 PM
ET Webcast URL: https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=F1263B20-BE46-4ECA-876D-F6FFD8F51EF3&Referrer=https%3A%2F%2Finvestors.biomarin.com%2F
Recent Stock Performance
52-week high: $131.94
52-week low: $71.35
Price action over last quarter: Up 0.74%
Company Profile
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
